tbuckley/cabot-search huggingface dataset:
Evaluation of an Anorexiant Drug
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reversible electrocardiographic changes associated with wasp sting anaphylaxis
Authors: G. W. Brasher
Journal: JAMA (1974)

DEATH from anaphylaxis in humans often results from laryngeal edema or acute pulmonary emphysema. In the following case, nearly fatal anaphylaxis after a wasp sting produced dramatic and reversible electrocardiographic changes. <h3>Report of a Case</h3> Twenty minutes after a wasp sting, a 62-year-old man with angina pectoris complained of shortness of breath, became confused, fell backwards, and turned a bluish color. He was rushed to the emergency room of Scott and White Memorial Hospital. Arriving at 10:52 AM, the patient was described by the admitting physician as "markedly dyspneic, sweaty and cyanotic, with bubbly white sputum running out of the mouth." The physician recorded a blood pressure of 120/90 mm Hg, and noted that "the lungs were tight with moist rales," and "heart tones were inaudible." Within five minutes, intermittent positive pressure breathing with oxygen was administered, as were hydrocortisone sodium succinate (Solu-Cortef), 100 mg, and furosemide (Lasix), 40 mg,
Die Lungentuberkulose.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, September 1 to October 1, 1966
Journal: JNCI Journal of the National Cancer Institute (1966)

Journal Article Manuscripts Approved for JNCI, September 1 to October 1, 1966 Get access JNCI: Journal of the National Cancer Institute, Volume 37, Issue 5, November 1966, Page 707, https://doi.org/10.1093/jnci/37.5.707 Published: 01 November 1966
FOREIGN CORRESPONDENCE.
Authors: None A. B.
Journal: JAMA (1883)

Paris, Sept. 25, 1883. The annual meeting of the French Association for the Advancement of Science was this year held at Rouen, the medical section of which was presided over by Dr. Jules Rochard, member of the Paris Academy of Medicine and Inspector General of Hospitals in the Marine Department. Some of the papers that were read on the occasion were most interesting, but even of these I can only select a few, and send you but brief extracts. Dr. Gallard, a well-known gynæcologist, made a communication on the physiology of menstruation-a subject, he said, that required to be revised, as there were two currents of opinion entertained in the profession as to its mechanism, some admitting the correlation that existed between the menstrual flow of blood and ovulation in the light of cause and effect, whilst others looked upon the presence of the two phenomena as a simple coincidence,
Abstract 2841: Endothelial Selective NF-κB Inhibition Improves Survival and Preserves Host Defense Capacity in Bacterial Model of Sepsis
Authors: Jianqiang Ding, Xiaobing Ye, Shu F Liu
Journal: Circulation (2007)

NF-κB plays a predominant role in septic pathology and is a desired target for developing therapies for septic shock. However, NF-κB blockade impairs bacterial clearance capability (BCC), which is detrimental. We have demonstrated that endothelial-restricted NF-κB blockade effectively prevents endotoxemic multiple organ injury (Circulation, 114: II-257). In this study, we examined whether endothelial-selective NF-κB blockade preserves BCC and improves survival in bacterial model of sepsis. Wild type (WT) and transgenic mice (TG) that conditionally overexpress a degradation-resistant I-κBα (I-κBαmt) selectively on endothelial cells were intravenously injected with saline (1 ml/kg) or pathogenic bacteria. Bacterial colonies formed in blood and tissue homogenate cultures of lungs, liver, spleen and kidney were counted. TG mice were induced to express I-κBαmt by feeding with doxycycline in drinking water. No bacteria grew in blood and any tissue homogenate culture from WT and TG mice injected with saline. Bacterial colony counts in blood and the 4 tissue homogenate cultures were similar between TW and TG mice 12 hrs after 10 7 CFU S. pneumoniae or 10 8 CFU S. enterica injection or 24 hrs after 10 8 CFU L. monocytogenes injection (Table ). TG mice showed an improved survival in the cecal ligation and puncture model of sepsis. The survival rate was 33% and 67% for WT and TG mice. Our results demonstrate that endothelial-selective blockade of NF-κB activation improves survival and preserves bacterial clearance capacity in bacterial model of sepsis. Bacterial Colony Counts (CFU per ml blood or gram tissue)
Correction
Journal: BMJ (1919)

has been President of the Association dtui ing the yetars of the war, and will preside over its Anniuial Meeting in Cambridge next year.The esteem due to Sir Clifford Allbutt's attainments and the warm affection inspired by lhis character are suclh that very many, both within and without the Association, will desire to slhare in this tribute to one wlhose career lhas reflected so mutch lhonour on medicine in England.This deesire will uot be limited to his many pupils, first in Leeds and afterwards in Camubridge, nor to the memnbers of the Association, and subscriptions are invited froi all imemb etsl of -the profession.
Reply
Authors: Anna Ragaz, A Bernard Ackerman
Journal: British Journal of Dermatology (1983)

Journal Article Reply Get access Anna Ragaz, Anna Ragaz Department of Dermatopathology, New York University Medical Center, 30 First Avenue, New York, NY 10016, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar A Bernard Ackerman A Bernard Ackerman Department of Dermatopathology, New York University Medical Center, 30 First Avenue, New York, NY 10016, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 108, Issue 6, 1 June 1983, Page 737, https://doi.org/10.1111/j.1365-2133.1983.tb01092.x Published: 01 June 1983
ApolipoproteinA-I (apoA-I) and markers of inflammation in coronary heart disease (CHD) Axel Schlitt, H. J. Rupprecht, S. Blankenberg, C. Bickel, G. Hafner*, G. Rippin**, J. Meyer. university clinic mainz, II. medical clinic, Mainz, Germany, *clinic of clinical chemistry, **institute for medical statistics, Mainz, Germany
Journal: Journal of the American College of Cardiology (2001)
Highlights
Authors: Howard Bauchner, L Wyner, William Didusch
Journal: JAMA (2019)

It is uncertain whether the risk of long-term mortality and stroke associated with atrial fi brillation (AF) can be mitigated by restoring sinus rhythm.Packer and colleagues for the CABANA Investigators randomized 2204 symptomatic patients with AF and found that catheter ablation, compared with medical therapy, did not reduce a composite end point of death, disabling stroke, serious bleeding, or cardiac arrest.In an Editorial, Albert and Bhatt suggest that patients who have disabling symptoms of AF may benefi t from catheter ablation, but patients who choose drug therapy will also likely experience signifi cant improvements in quality of life and have no worse risk for stroke or death.
Abstract 4591: Overexpression of p62/IMP2 can promote cell migration in hepatocellular carcinoma (HCC) via activating Wnt/ <i>β</i>-<i>catenin</i> pathway
Authors: Mengtao Xing, Jianxiang Shi, Pei Li, Jiejie Qin, Xiaojun Zhang, Yangcheng Ma, Xiao Wang, Giulio Francia, Jianying Zhang
Journal: Cancer Research (2019)

Abstract There are three members in the family of insulin-like growth factor 2 mRNA binding proteins (IMP): IMP1, IMP2 and IMP3. The IMPs are oncofetal proteins, expressed during embryogenesis and lost in most tissues in adults. However, IMPs were found overexpressed in various cancers. IMPs share similar protein structure in mammals and have similar functions: to bind specific mRNAs, regulate their expression, transportation, and degradation. Although p62/IMP2 was first reported as a tumor-associated antigen in HCC around 20 years ago, we still know little about the role of p62/IMP2 in HCC progression. Our previous studies found that p62/IMP2 was not only overexpressed in HCC tissues, but also overexpressed in HCC cell lines. To explore the biological roles of p62/IMP2 in HCC progression, p62/IMP2 was knockout in two p62/IMP2 positive HCC cell lines (SNU449, HepG2). Due to the low expression level of p62/IMP2 in SNU449, we performed the transfection experiment to overexpress p62/IMP2 in this cell line. The Wound healing assay and transwell migration assay indicated that overexpressed p62/IMP2 in both cell lines showed the ability that could promote the cell migration significantly (p&amp;lt;0.05). On the contrary, the lack of p62/IMP2 expression can reduce the cell migration ability (P&amp;lt;0.05). After analyzing the HCC expression data from Gene Expression Omnibus (GEO), the high and low IMP2 expression groups were set up based on the median expression of p62/IMP2 from GSE 14520. Three genes were selected in differential gene expression analysis with a cancer-metastasis related gene profile, including CTNNB1, ACTR2, VASP (LogFC &amp;gt; 0.3, Adj. p&amp;lt;0.001). Then we performed a western blotting analysis to explore the effect of overexpressed p62/IMP2 on Wnt/β-catenin pathway-related proteins. Overexpressed p62/IMP2 significantly enhance the expression of Wnt and β-catenin, whereas inhibiting the expression of Gsk3b and E-cadherin. Moreover, the migration ability of SNU449 and HepG2 cells were significantly reduced (p&amp;lt;0.05) after cultured with 10mM Wnt/β-catenin signaling pathway inhibitor XAV939 for 24h. In summary, our data showed that overexpressed p62/IMP2 can enhance the migration ability of HCC cells via activating Wnt/β-catenin signaling pathway. Citation Format: Mengtao Xing, Jianxiang Shi, Pei Li, Jiejie Qin, Xiaojun Zhang, Yangcheng Ma, Xiao Wang, Giulio Francia, Jianying Zhang. Overexpression of p62/IMP2 can promote cell migration in hepatocellular carcinoma (HCC) via activating Wnt/ β-catenin pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4591.
Respiratory Failure
Authors: C. M. Ogilvie
Journal: BMJ (1965)

<b>Background:</b> Lung cancer is the leading cause of cancer death in the UK. There is pressure to expedite the diagnostic pathway. This study aimed to evaluate patients with haemoptysis to determine whether investigations could be rationalised. <b>Methods:</b> Patients referred to two UK rapid-access lung cancer clinics between 01/01/2017 &amp; 31/12/2017 were included. Electronic case records &amp; imaging were reviewed for patient characteristics, investigations &amp; final diagnoses. <b>Results:</b> 835 patients were identified. 216/835 presented with haemoptysis (Table 1). 41/216 patients with haemoptysis were diagnosed with cancer; all had abnormal CT, although 3 had a normal CXR. 84/216 patients with haemoptysis had normal CTs. 41 of these had a bronchoscopy. No patient with a normal CT was diagnosed with cancer. Haemoptysis alone had a positive predictive value (PPV) for a non-cancer diagnosis of 81.0%, with a specificity of 83.2%. Haemoptysis &amp; normal CXR had a 97.4% PPV for non-cancer, with a specificity of 98.8%. Haemoptysis &amp; normal CT was 100% specific for a non-cancer diagnosis. <b>Conclusion:</b> British Thoracic Society Guidelines recommend bronchoscopy in patients with haemoptysis and a normal CT if there is a high suspicion of lung cancer. These data, from a large, representative patient population, suggest that CT imaging can reliably exclude cancer in patients with haemoptysis, and therefore bronchoscopy may not be indicated.
Abstract 5298: Finding new molecules to bypass the tumor suppressor gene TP53 and restore cell cycle checkpoint control
Authors: Henry Moore, Jessica Blackburn
Journal: Cancer Research (2019)

Abstract The tumor suppressor gene, tumor protein 53 (TP53), has been shown to be mutated in more than half of all human cancer cases. p53 controls the G1/S phase checkpoint of the mitotic cell cycle, protecting the fidelity of DNA and inducing apoptosis in cells with irreparable DNA damage. Mutations in TP53, which are often missense mutations that interfere with p53 DNA binding activity or protein folding, result in protein inactivation and loss of checkpoint control, allowing cells with potentially oncogenic mutations to survive and proliferate. TP53 mutations have been shown to enhance tumor progression, increase metastatic potential, and mediate chemotherapy resistance. Because of the importance of p53 in cancer, many studies have aimed to identify small molecules that can “reactivate” mutated p53 protein in cell culture, although this has met with little success thus far. The aim of this research is to identify the extent to which the effects of non-functioning p53 can be completely bypassed, and cell cycle checkpoint restored, using already-established FDA approved compounds in a zebrafish model of p53 loss. Zebrafish were genetically engineered to have their entire TP53 locus removed using TALEN (Transcription activator-like effector nuclease), rendering them unable to produce the p53 protein. p53 deficient and wild-type zebrafish larvae were then subjected to gamma-irradiation to induce DNA damage. An apoptotic cell staining assay was then performed to allow for the qualitative and quantitative analysis of apoptosis levels throughout the larvae. As expected, TP53 null fish had significantly less apoptotic cells than control after DNA damage. We are in the process of testing 770 FDA approved compounds for their effects in inducing an apoptotic response in p53 null larvae after gamma-irradiation. Positive hits will be carried forward to human cancer cells with TP53 mutation, and the mechanism of action of the drug will be determined using biochemical approaches. These results could identify novel pathways that work in concert with p53 and will allow us to harness new mechanisms of DNA damage induced apoptosis to kill cancer cells. Repurposing FDA-approved drugs can also rapidly translate to clinical benefit in a wide number of cancers driven by TP53 mutation. Citation Format: Henry Moore, Jessica Blackburn. Finding new molecules to bypass the tumor suppressor gene TP53 and restore cell cycle checkpoint control [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5298.
Diagnostic Neuroradiology
Authors: Harold O. Peterson
Journal: JAMA (1965)

This monumental work covers the entire field of diagnostic neuroradiology. The authors have done an excellent job in depicting their unusually rich experience. The book is intended as a text for students, a handbook for those in the graduate study of radiology, and a record of the working principles of neuroradiology found useful by the authors. While it is too difficult for medical students, it is an excellent text for those moderately well versed in the field of neuroradiology. The first section of 228 pages, dealing with the plain-film examination of the skull, has perhaps too few illustrations of the normal. The use of arrows to point out areas of interest often makes it difficult to correlate the illustrations and the captions. Most of the illustrations are reasonably good, although some do not demonstrate well what they are intended to show. Some lesions of the bony skull are almost entirely
Physiologie und Pathologie der Leber nach ihrem heutigen Stande.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An aid to patient compliance
Authors: R. D. Gillette
Journal: JAMA (1980)

<h3>To the Editor.—</h3> No controversy would have arisen over the University Group Diabetes Program results and it is unlikely that the data would have been reexamined had the report confirmed diabetologists' preconceived notion that lowering blood sugar levels of diabetic patients prevents complications and prolongs life. I cannot help but reflect on the controversy that would have arisen had the "Five-Year Findings of the Hypertension Detection and Follow-up Program" (242:2562, 1979) not reported benefits from treating hypertension. Since it did, little attention will be paid to the fact that the first-year mortality of the stepped care group was better than the normal expected rate, there were more diabetics in the referred care group, it contained more who died of noncardiovascular causes, the results were not significantly different in severe hypertensives, and, during the five years of observation, there was no progressive increase in mortality difference between the stepped care and
Incorrect Statement
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROPHYLAXIS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Giving Bad News to Cancer Patients: Matching Process and Content
Authors: Walter F. Baile, Estela A. Beale
Journal: Journal of Clinical Oncology (2001)

Article Tools THE ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.9.2575 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11331340 Giving Bad News to Cancer Patients: Matching Process and Content Walter F. BailexWalter F. BaileSearch for articles by this author , Estela A. BealexEstela A. BealeSearch for articles by this author Show More From the Section of Psychiatry, Department of Neuro Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. https://doi.org/10.1200/JCO.2001.19.9.2575 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology